CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to improve how the risk of developing ovarian cancer is assessed in people who may be at increased risk of ovarian cancer due to their family history or genetic background. In current clinical practice, ovarian cancer risk assessment usually relies on information about cancer in the family and, in some cases, genetic testing for certain genes known to be associated with ovarian cancer. While this approach is commonly used, the inclusion of additional factors may support more personalised ovarian cancer risk assessment. This study compares two approaches to ovarian cancer risk assessment: * Standard clinical practice, which follows current national guidelines, and * A more personalised risk assessment, which uses a validated tool called CanRisk, recommended by European guidelines, to combine family history, genetic test results, and other factors, including health and lifestyle-related factors. By comparing these two approaches, the study aims to understand whether the personalised risk assessment tool, CanRisk, can be used in everyday clinical care. To do this, researchers will investigate whether the CanRisk tool is feasible in clinical practice, acceptable to both healthcare professionals and persons receiving a risk assessment, as well as whether it can be delivered in a cost-effective way. The study does not involve people who have been diagnosed with ovarian cancer. It focuses on individuals who are currently cancer-free and are undergoing assessment because they may have an increased risk of ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety, osoby transpłciowe lub niebinarne posiadające żeńskie narządy rozrodcze
- •Wiek od 18 do 75 lat
- •Skierowanie ze względu na rodzinną historię raka jajnika lub zmianę genetyczną powiązaną z tym rakiem w rodzinie
- •Zdolność do wyrażenia świadomej zgody
- •Pozostanie w okolicy badania na czas jego trwania
✗ Disqualifies
- •Wcześniejszy lub obecny nowotwór
- •Wcześniejsza chirurgiczna usunięcie jajników w celach profilaktycznych
- •Wcześniejsza ocena ryzyka przy użyciu narzędzi jak CanRisk
- •Jakikolwiek stan mogący utrudnić uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 29, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (6)
Vseobecna Fakultni Nemocnice V Praze
Prague, Czechia
Fakultni Nemocnice Bulovka
Prague, Czechia
National Centre for Scientific Research Demokritos
Athens, Greece
Dept of Clinical Therapeutics, Alexandra Hospital
Athens, Greece
Lithuanian University of Health Sciences
Kaunas, Lithuania
Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.
Lisbon, Portugal
Trial contact
Fatima VAZ
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.